Loading...
Market
How many new gene therapy treatments using SmartFlow Cannula will be announced by 2025?
2
Resolution / Starting Odds
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
Press releases from ClearPoint Neuro or collaborating institutions
Story
ClearPoint Neuro ($CLPT) Gains FDA Approval for SmartFlow Cannula, First Direct Gene Therapy Delivery to Brain, Shares Up 10.9%
Nov 14, 2024, 01:20 PM
ClearPoint Neuro, trading under the ticker symbol $CLPT, has received FDA De Novo marketing authorization for its SmartFlow Cannula, marking a significant advancement in the delivery of gene therapy directly to the brain. This approval is particularly notable as it represents the first direct local delivery of neurological gene therapy in the United States, aimed at treating severe diseases, primarily affecting young children. The stock has seen a positive response, with a pre-market increase of 10.9%. The authorization is expected to open up new opportunities in the field of gene therapy, potentially transforming treatment options for patients suffering from debilitating conditions.
View original story
Similar markets
Yes • 50%
No • 50%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
21+ • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
